Pan-tuberculosis regimens: an argument for

Lancet Respir Med. 2018 Apr;6(4):239-240. doi: 10.1016/S2213-2600(18)30096-1.

Authors

Robert S Wallis¹, Ted Cohen², Nicolas A Menzies³, Gavin Churchyard⁴

Affiliations

¹ Aurum Institute, Johannesburg, South Africa. Electronic address: rwallis@auruminstitute.org.
² Yale University, New Haven, CT, USA.
³ Harvard TH Chan School of Public Health, Boston, MA, USA.
⁴ Aurum Institute, Johannesburg, South Africa.

PMID: 29595501
DOI: 10.1016/S2213-2600(18)30096-1

No abstract available

Publication types

Comment

MeSH terms

Antitubercular Agents*
Drug Therapy, Combination
Humans
Mycobacterium tuberculosis
Tuberculosis*

Substances

Antitubercular Agents